T

    Teleflex Incorporated (TFX)

    Official site

    HEALTHCARE • MEDICAL INSTRUMENTS & SUPPLIES • NYSE

    $139.67
    +1.96 (+1.42%)

    Market Cap: $5.92B

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    98%(39/40)
    Avg Surprise
    +7.28%
    Streak
    2 Q

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$1.89
    Range$1.76 - $2.04
    12 analysts
    EPS Revisions
    6
    0
    7d
    6
    1
    30d
    EPS Estimate Drift
    90d ago$1.82-3.4%
    60d ago$1.83-3.0%
    30d ago$1.82-3.5%
    7d ago$1.89+0.0%
    Current$1.89
    Revenue Consensus
    $565M
    Range$564M - $570M
    12 analysts
    Dec 31, 2026
    EPS Consensus$2.68
    Range$2.62 - $2.87
    11 analysts
    Revenue Consensus
    $606M
    Range$601M - $611M
    13 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$2.68---
    Sep 26EST
    		-$1.89---
    Jun 26
    		$1.76$1.28+37.50%Beat-52.8%
    Mar 26
    		$1.39$1.21+14.88%Beat-52.2%
    Dec 25
    		$1.93$3.73-48.26%Miss-50.4%
    Sep 25
    		$3.67$3.38+8.58%Beat+5.2%
    Jun 25
    		$3.73$3.37+10.68%Beat+9.1%
    Mar 25
    		$2.91$2.88+0.89%Beat-9.3%
    Dec 24
    		$3.89$3.88+0.26%Beat+15.1%
    Sep 24
    		$3.49$3.39+2.95%Beat-4.1%
    Jun 24
    		$3.42$3.33+2.70%Beat+0.3%
    Mar 24
    		$3.21$3.07+4.56%Beat+3.9%
    Dec 23
    		$3.38$3.26+3.68%Beat-4.0%
    Sep 23
    		$3.64$3.27+11.31%Beat+11.3%
    Jun 23
    		$3.41$3.21+6.23%Beat+0.6%
    Mar 23
    		$3.09$2.98+3.69%Beat+7.3%
    Dec 22
    		$3.52$3.44+2.33%Beat-2.2%
    Sep 22
    		$3.27$3.11+5.14%Beat-6.8%
    Jun 22
    		$3.39$3.34+1.50%Beat+1.2%
    Mar 22
    		$2.88$2.72+5.88%Beat+0.3%
    Dec 21
    		$3.60$3.53+1.98%Beat+10.8%
    Sep 21
    		$3.51$3.03+15.84%Beat+26.7%
    Jun 21
    		$3.35$2.87+16.72%Beat+73.6%
    Mar 21
    		$2.87$2.42+18.59%Beat+5.5%
    Dec 20
    		$3.25$3.05+6.56%Beat-0.9%
    Sep 20
    		$2.77$2.24+23.66%Beat-6.7%
    Jun 20
    		$1.93$1.25+54.40%Beat-27.4%
    Mar 20
    		$2.72$2.24+21.43%Beat+21.4%
    Dec 19
    		$3.28$3.22+1.86%Beat+18.4%
    Sep 19
    		$2.97$2.75+8.00%Beat+17.9%
    Jun 19
    		$2.66$2.59+2.70%Beat+7.7%
    Mar 19
    		$2.24$2.17+3.23%Beat+4.2%
    Dec 18
    		$2.77$2.76+0.36%Beat+13.5%
    Sep 18
    		$2.52$2.42+4.13%Beat+18.9%
    Jun 18
    		$2.47$2.41+2.49%Beat+21.1%
    Mar 18
    		$2.15$1.94+10.82%Beat+19.4%
    Dec 17
    		$2.44$2.40+1.67%Beat+14.6%
    Sep 17
    		$2.12$2.00+6.00%Beat+17.8%
    Jun 17
    		$2.04$1.91+6.81%Beat-
    Mar 17
    		$1.80$1.69+6.51%Beat-
    Dec 16
    		$2.13$2.09+1.91%Beat-
    Sep 16
    		$1.80$1.78+1.12%Beat-

    Dividends

    Dividend Metrics

    Yield0.97%
    Annual/Share$1.36
    Payout Ratio38.46%
    Frequency4
    Pay MonthsMar, Jun, Sep, Dec

    Growth

    3Y CAGR+0.00%
    5Y CAGR+0.00%
    View TFX's full dividend history

    Key Metrics

    Valuation
    P/E Ratio15.96EV/EBITDA32.86x
    Price/FCF67.13xFCF Yield1.49%
    Profitability
    Profit Margin-45.80%Operating Margin14.40%
    ROE-0.70%ROIC1.42%
    Financial Health
    Debt/Equity0.97xInterest Coverage1.18x
    Current Ratio2.60xQuick Ratio2.12x
    Trading Statistics
    Beta0.81Avg Volume629.96K
    52-Week High$144.6452-Week Low$99.39

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$136.93
    SMA 20$136.70
    SMA 50$133.43
    SMA 200$121.90
    EMA 10$137.72
    EMA 20$136.58
    EMA 50$134.00
    EMA 200$126.62

    MACD

    Line: 1.43Signal: 1.17Hist: 0.25

    ADX

    ADX: 11.5+DI: 17.4-DI: 18.7

    Aroon & PSAR

    Aroon Up36.0
    Aroon Down36.0
    PSAR$141.09

    Bollinger Bands

    Upper Band$141.86
    Lower Band$131.54
    %B Position755%(Upper)
    Band Width0.79

    RSI (14-Day)

    Neutral
    57.3

    Momentum Oscillators

    Stoch %K80.8
    Stoch %D74.0
    Williams %R-9.3
    ROC (10d)1.8%
    Momentum2.50
    CCI (20d)84.0
    MFI (14d)69.4

    Volatility Measures

    ATR (14d)$4.10(2.9%)
    StdDev (20d)2.58
    Hist Vol28.3%(Moderate)

    Volume Flow

    VWAP$139.20
    OBV6.8M
    AD Line-92.2M
    CMF (20d)-0.156

    Volume Metrics

    Avg Vol (20d)646.3K
    Vol Ratio0.7x
    VWMA (20d)$136.69

    Pivot Points

    R3$140.59
    R2$139.55
    R1$138.63
    Pivot Point$137.59
    S1$136.67
    S2$135.63
    S3$134.71

    Advanced Oscillators

    TSI9.82
    Ultimate Osc58.0
    KST24.19

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$570.33M$548.26M$-401,866,000$913.02M$442.52M$414.26M$-552,369,000$764.38M$749.69M$737.85M$-488,139,000$746.39M
    Cost of Revenue$238.63M$240.84M$-250,454,000$461.38M$176.69M$158.83M$-326,992,000$334.20M$333.23M$321.71M$-312,737,000$330.08M
    Gross Profit$331.71M$307.43M$-151,412,000$451.64M$265.83M$255.43M$-225,377,000$430.17M$416.46M$416.13M$-175,402,000$416.31M
    Operating Expenses$258.88M$287.24M$-397,802,000$860.54M$174.69M$179.63M$-67,632,000$280.86M$299.58M$420.93M$-10,282,000$251.00M
    R&D$45.12M$44.39M$12.63M$57.23M$26.49M$25.30M$-8,098,000$38.73M$41.09M$37.30M$-4,866,000$37.58M
    SG&A$213.51M$226.01M$614,000$281.76M$137.50M$152.91M$-66,198,000$247.26M$250.63M$242.83M$-46,476,000$213.19M
    Operating Income$72.82M$20.18M$246.39M$-408,898,000$91.14M$75.80M$-157,745,000$149.31M$116.88M$-4,793,000$-165,120,000$165.31M
    Interest Income$1.42M$1.71M$680,000$2.16M$1.23M$1.49M$401,000$2.30M$1.79M$1.67M$2.19M$7.49M
    Interest Expense$29.10M$25.72M$28.13M$31.84M$21.70M$18.54M$18.60M$21.06M$21.17M$22.68M$25.72M$23.19M
    Income Before Tax$45.14M$-3,827,000$218.94M$-438,576,000$70.66M$58.75M$-175,948,000$130.55M$97.50M$-25,810,000$-188,650,000$149.60M
    Income Tax Expense$3.38M$1.01M$-30,779,000$-29,699,000$2.49M$6.42M$-26,315,000$19.63M$17.33M$-41,551,000$-5,778,000$11.94M
    Net Income$99.69M$-8,154,000$-714,330,000$-408,892,000$122.58M$95.00M$-136,656,000$111.00M$80.04M$15.29M$31.11M$137.14M
    EBITDA$124.14M$75.41M$214.65M$-329,497,000$128.88M$115.27M$-198,167,000$218.79M$185.87M$62.10M$-194,079,000$223.75M
    EBIT$72.82M$20.18M$246.39M$-408,898,000$91.14M$75.80M$-157,745,000$149.31M$116.88M$-4,793,000$-165,120,000$165.31M
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about TFX

    Government Contracts

    Gov Obligations (TTM)
    $430786
    Gov Obligations / Revenue
    0.0%
    Obligations YoY
    -79.8%
    Active Awards
    130
    New Awards (TTM)
    109
    Avg Remaining Term
    12.5 mo

    Top agency: Department of Health and Human Services at 47.8% of trailing twelve month obligations across 3 agencies

    Recent Awards

    Award IDAgencyObligatedStart
    36C25926P0550Department of Veterans AffairsDepartment of Veterans Affairs$42120Jul 10, 2026
    36C25226P0212Department of Veterans AffairsDepartment of Veterans Affairs$41300Apr 21, 2026
    36C25026P0825Department of Veterans AffairsDepartment of Veterans Affairs$39524Jul 24, 2026
    36C24826P0776Department of Veterans AffairsDepartment of Veterans Affairs$30043Jun 8, 2026
    75H71025P01195Department of Health and Human ServicesIndian Health Service$21500Sep 17, 2025
    36C26026P0129Department of Veterans AffairsDepartment of Veterans Affairs$18900Dec 5, 2025
    36C24226P0544Department of Veterans AffairsDepartment of Veterans Affairs$17843Apr 9, 2026
    36C26126P0828Department of Veterans AffairsDepartment of Veterans Affairs$15163Jul 1, 2026
    SPE2DS25P1535Department of DefenseDefense Logistics Agency$9000Aug 11, 2025
    SPE2DS25P1508Department of DefenseDefense Logistics Agency$9000Aug 5, 2025

    Federal contract obligations are bookings recorded by the awarding agency, not recognized revenue. They can exceed 100% of revenue and can be negative when contracts are de-obligated. Source: USAspending.gov prime awards, data through Jul 31, 2026.

    News

    Is TFX a Buy Now as Valuation Improves but Execution Risks Remain?

    Teleflex (TFX) presents a more attractive valuation with its stock trading below industry averages and its five-year median. The company has also improved its financial standing through debt reduction and share repurchases, and raised its 2026 earnings guidance. However, the investment case is tempered by ongoing execution risks including slower integration of its Vascular Intervention business, unfinished divestitures, and margin pressures from competition and tariffs.

    TradingView•8/25/26•
    Somewhat-Bullish

    Needham raises Teleflex stock price target on Freesolve potential

    Needham raised its price target for Teleflex Inc. (NYSE:TFX) to $170 from $159, maintaining a Buy rating, due to the potential of its Freesolve product. The firm anticipates Freesolve, a novel coronary scaffold, to significantly boost international sales by 2028 and contribute 1-2% to annual revenue growth. This outlook comes as Teleflex also reported strong Q2 2026 financial results, exceeding revenue and EPS expectations.

    Investing.com•8/25/26•
    Bullish

    Needham Adjusts Price Target on Teleflex to $170 From $159, Maintains Buy Rating

    Needham has increased its price target for Teleflex (TFX) from $159 to $170, while reiterating a Buy rating on the stock. This adjustment reflects an updated outlook from the analyst firm on the medical technology company.

    marketscreener.com•8/25/26•
    Bullish

    Can Teleflex's OEM Sale and Higher EPS Outlook Reshape 2026 Returns?

    Teleflex (TFX) recently sold its OEM business for $1.5 billion, significantly reducing its debt and improving its balance sheet. This strategic move led the company to raise its 2026 adjusted earnings outlook, despite cutting its revenue growth forecast. While capital allocation benefits are clear, the company still faces margin pressure and a pending divestiture of its Acute Care and Interventional Urology businesses.

    TradingView•8/24/26•
    Somewhat-Bullish

    Teleflex stock holds recent gains as INGENYX carve-out reshapes its medtech profile

    Teleflex stock has seen a 5% gain over the past year, outperforming its industry, driven by its strategic carve-out of the Medical OEM unit into an independent company, INGENYX. This move allows Teleflex to focus on its core interventional and surgical product lines, supported by a strong long-term earnings growth estimate of 20.7% and a history of beating analyst expectations. The company's performance, particularly in its Arrow vascular access portfolio, positions it as a resilient medtech investment despite broader market volatility.

    Ad-hoc-news.de•8/21/26•
    Bullish

    Frequently Asked Questions About TFX

    What is TFX's current dividend yield?
    Teleflex Incorporated (TFX) has a current dividend yield of 0.97%.
    Does TFX pay dividends?
    Yes, Teleflex Incorporated pays dividends with a current yield of 0.97%.
    What is TFX's P/E ratio?
    Teleflex Incorporated has a price-to-earnings (P/E) ratio of 15.96.
    What is TFX's market cap?
    Teleflex Incorporated (TFX) has a market capitalization of $5.92B with a current stock price of $139.67.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In